Johnson & Johnson Innovation – JJDC

Type

CVC

Status

Active

Location

New Brunswick, United States

Total investments

90

Average round size

48M

Portfolio companies

66

Rounds per year

1.76

Lead investments

16

Follow on index

0.27

Exits

6

Areas of investment
BiotechnologySoftwareHealth CareHealth DiagnosticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

The leading representative office of defined VC is situated in the Cambridge. The company was established in North America in United States. Johnson & Johnson Innovation u2013 JJDC appeared to be a CVC structure as part of the corporation.

The increased amount of exits for fund were in 2018. Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. This Johnson & Johnson Innovation u2013 JJDC works on 23 percentage points less the average amount of lead investments comparing to the other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The important activity for fund was in 2019. The fund is generally included in 2-6 deals every year.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Johnson & Johnson Innovation u2013 JJDC, startups are often financed by Wildcat Capital Management, Johnson & Johnson Development Corporation, TPG Biotech. The meaningful sponsors for the fund in investment in the same round are Wildcat Capital Management, Whittier Ventures, VSP Global. In the next rounds fund is usually obtained by dRx Capital, Lux Capital, Lightstone Ventures.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Memebox, Fusion Pharmaceuticals, X-Vax Technology We can highlight the next thriving fund investment areas, such as Pharmaceutical, Therapeutics. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.

Show more

Investor highlights

Industry focus
HealthcareBiotech/Life SciencesMedtechConsumer/RetailAI/Big Data
Stage focus
SeedSeries ASeries B

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
90
Lead investments
16
Exits
6
Rounds per year
1.76
Follow on index
0.27
Investments by industry
  • Health Care (56)
  • Biotechnology (53)
  • Medical (42)
  • Medical Device (27)
  • Therapeutics (23)
  • Show 38 more
Investments by region
  • United States (62)
  • United Kingdom (6)
  • Israel (8)
  • Canada (1)
  • Switzerland (1)
  • Show 7 more
Peak activity year
2020

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
8
Avg. valuation at time of investment
37M
Group Appearance index
0.91
Avg. company exit year
4
Avg. multiplicator
2.98

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Bright Peak Therapeutics 11 Jun 2024 Biotechnology, Therapeutics Late Stage Venture 90M Switzerland, Basel-City, Basel
ROME Therapeutics 12 Sep 2023 Biotechnology, Health Care, Pharmaceutical Early Stage Venture 72M United States, Massachusetts, Cambridge
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.